Revenue segments as reported by the company.

Medical Devices

Specialty Pharmaceuticals

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Royalty expense

Amortization expense

Intangible asset impairment charges

Contingent consideration net expense (benefit)

Restructuring net charges (credits)

Litigation-related net charges (credits)

Gain on disposal of businesses and assets

Goodwill impairment charges

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Boston Scientific

Boston Scientific Corp. engages in the development, manufacture and marketing of medical devices that are used in interventional medical specialties. It operates through the following segments: Rhythm and Neuro, Cardiovascular and MedSurg. The Rhythm and Neuro segment develops implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities. The Cardiovascular segment consists of technologies for diagnosing and treating coronary artery disease and other cardiovascular disorders including structural heart conditions. The MedSurg segment focuses on Endoscopy, which provides devices to diagnose and treat a broad range of gastrointestinal and pulmonary conditions with innovative and invasive technologies. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979, and is headquartered in Marlborough, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Boston Scientific reports solid Q4 performance and eyes global growth

Boston Scientific's Q4 performance was solid, with growth across regions and business units.
Challenges include potential sales growth hurdles in Q1 2023 and headwinds from tough comps and market adjustments.
Opportunities lie in continued momentum in key business units, successful product launches, and global growth prospects.
The company remains focused on sustaining growth, expanding margins, and delivering double-digit adjusted EPS growth.

Boston Scientific surpasses Q1 expectations, eyes growth through Farapulse

Boston Scientific's Q1 '23 earnings call showcased strong performance, with exceeding revenue expectations and solid organic sales growth. The company's strategic focus on high-growth M&A, resolving supply constraints for Farapulse, and capital allocation priorities position it well for future growth. Challenges include potential earnings dilutive deals and addressing free cash flow conversion challenges.

Boston Scientific surpasses Q2 expectations, eyes margin expansion and innovation

Boston Scientific delivered a strong Q2 '23 performance, exceeding expectations with robust sales growth and improved adjusted EPS, driven by strong performance across key regions and business segments.
While facing challenges such as inflation impact and market dynamics, the company remains focused on opportunities for margin expansion, product innovation, and strategic acquisitions to drive future growth.
With a positive outlook for the coronary business, upcoming product launches, and a commitment to operational excellence, Boston Scientific aims to maintain its competitive edge and capitalize on market opportunities.
Anticipated results from trials, market potential for new products, and a focus on sustainable growth strategies position Boston Scientific for continued success and market leadership in the healthcare sector.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities ahead

Boston Scientific's Q3 2023 results exceeded expectations, with strong performance across regions and business units.
The company raised full-year guidance, expecting organic revenue growth of approximately 11% and adjusted EPS range of $1.99 to $2.02.
Challenges in the Neuromodulation business and cost impacts are being addressed for future improvement.
Opportunities lie in acquisitions, FDA approvals, and strategic commercial initiatives for growth and margin expansion.

Boston Scientific (BSX) exceeds Q4 expectations, eyes growth opportunities

Boston Scientific (BSX) reported impressive Q4 2023 results, exceeding sales and EPS guidance.
The company showcased strong regional growth, highlighted key products, and outlined solid 2024 outlook.
While facing challenges like delayed product launches and market disruptions, BSX remains focused on growth opportunities.
Strategic acquisitions and margin improvement initiatives position Boston Scientific for continued success in the future.

Boston Scientific beats Q1 expectations, eyes growth in key markets

Boston Scientific delivered strong Q1 results, exceeding expectations and showcasing growth across key regions and business units.
While facing challenges like inventory charges, the company is focused on leveraging opportunities in expanding product indications and enhancing capabilities.
With raised full-year guidance and a focus on innovation and market expansion, Boston Scientific is poised for continued growth and success in 2024.

Boston Scientific (BSX) reports stellar Q2 results and eyes sustained growth

Boston Scientific's Q2 2024 performance exceeded expectations, showcasing strong financial results and regional sales growth across key markets.
The company's strategic strengths lie in diversified business units, innovative products like FARAPULSE, and strategic acquisitions like Silk Road Medical.
While challenges exist in adoption metrics and margin expansion, BSX's focus on reinvestment and growth opportunities position it well for sustained success.

Boston Scientific surpasses Q3 expectations, eyes growth opportunities in Asia

Boston Scientific's Q3 performance exceeded expectations, driven by strong sales growth and increased adjusted EPS.
The company's focus on innovation and strategic investments in key business units like Cardiology and Neuromodulation bode well for future growth.
Despite challenges in China and the need to deliver on growth targets, Boston Scientific remains confident in its ability to sustain top-tier financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Boston Scientific Corp. engages in the development, manufacture, and marketing of medical devices that are used in interventional medical procedures. It operates through the MedSurg and Cardiovascular segments. The MedSurg segment includes Endoscopy, Urology, and Neuromodulation. The Cardiovascular segment consists of Cardiology and Peripheral Interventions. The company was founded by John E. Abele and Pete Michael Nicholas on June 29, 1979 and is headquartered in Marlborough, MA.

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in the legacy business from the pandemic mayhem.

Boston Scientific (BSX) Q1 Earnings Top, 2022 Revenue View Up

Boston Scientific Corporation (NYSE:BSX ) Q1 2022 Earnings Conference Call April 27, 2022 8:00 AM ET Company Participants Lauren Tengler - Vice President, Investor Relations Mike Mahoney - Chairman & Chief Executive Officer Dan Brennan - Executive Vice President & Chief Financial Officer Ken Stein - Chief Medical Officer Conference Call Participants Robbie Marcus - JPMorgan Rick Wise - Stifel Joanne Wuensch - Citibank Larry Biegelsen - Wells Fargo Vijay Kumar - Evercore ISI Travis Steed - Bank of America Danielle Antalffy - SVB Leerink Cecilia Furlong - Morgan Stanley Matthew O'Brien - Piper Sandler Operator Good morning, and welcome to the Boston Scientific First Quarter 2022 Earnings Call. All participants will be in listen-only mode.

Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q1 2022 Results - Earnings Call Transcript

Boston Scientific Corp (NYSE: BSX) generated net sales of $3.026 billion in Q1 FY22, beating the Wall Street estimate of $2.95 billion. Sales increased 10% Y/Y on a reported basis, 12.6% on an operational basis, and 9.7% on an organic basis, better than the management estimate of.

Boston Scientific Jumps On Upbeat Q2, FY22 Guidance

Boston Scientific (BSX) delivered earnings and revenue surprises of 2.63% and 2.45%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

Boston Scientific (BSX) Tops Q1 Earnings and Revenue Estimates

Boston Scientific Corp. shares BSX, -4.46% rose 3.3% premarket Wednesday, after the medical device maker reported lower earnings for the first quarter than a year ago but still beat consensus estimates. The company posted net income of $97 million, or 7 cents a share, for the quarter, down from $327 million, or 23 cents a share, in the year-earlier period.

Boston Scientific tops estimates for Q1, sending shares up 3.3% premarket

MARLBOROUGH, Mass. , April 27, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) generated net sales of $3.026 billion during the first quarter of 2022, growing 10.0 percent on a reported basis, 12.6 percent on an operational1 basis and 9.7 percent on an organic2 basis, all compared to the prior year period.

BOSTON SCIENTIFIC ANNOUNCES RESULTS FOR FIRST QUARTER 2022

Revenues expected to be slightly above the consensus estimates Trefis estimates Boston Scientific's Q1 2022 revenues to be around $3.0 billion, slightly above the $2.9 billion consensus estimate.

What To Expect From Boston Scientific Stock Following Q1 Earnings?

MARLBOROUGH, Mass. , April 1, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE:BSX) will webcast its conference call discussing financial results and business highlights for the first quarter ended March 31, 2022, on Wednesday, April 27, 2022, at 8:00 a.m.

Boston Scientific Announces Conference Call Discussing First Quarter 2022 Results

MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the pricing terms of the previously announced upsized cash tender offer (the "Tender Offer") for $2,852,561,000 in aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes identified in the table and the related notes below (the "Securities").

Boston Scientific Announces Pricing Terms of Its Cash Tender Offer

MARLBOROUGH, Mass., March 16, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced that, pursuant to the previously announced cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount of the outstanding senior notes identified in the table and the related notes below (the "Securities"), $5,139,194,000 in aggregate principal amount of the Securities were validly tendered and not validly withdrawn on or prior to 5:00 p.m.

Boston Scientific Announces Early Results of Its Cash Tender Offer for Its Outstanding Debt Securities and Increases Aggregate Maximum Principal Amount of Its Cash Tender Offer

The current headwinds around Boston Scientific (BSX) include the cost of running plants with COVID-specific measures, increased freight costs, price pressure and higher direct labor wages.

Boston Scientific (BSX) Hurt by Price and Volume Issues

Boston Scientific's M&A strategy has led to decreasing ROI from its acquisitions over the past 5 years from 5.97% in 2017 to 1.09% in 2021.

Boston Scientific: Weak M&A Strategy Weighing Down Price Target

MARLBOROUGH, Mass., March 8, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) (the "Company") today announced that American Medical Systems Europe B.V.

Boston Scientific Announces Completion of €3.0 Billion Offering of Senior Notes

Boston Scientific (BSX) reported earnings 30 days ago. What's next for the stock?

Boston Scientific (BSX) Up 3.2% Since Last Earnings Report: Can It Continue?

MARLBOROUGH, Mass., March 4, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE: BSX) today announced that American Medical Systems Europe B.V.

Boston Scientific Announces Pricing of €3.0 Billion of Senior Notes

MARLBOROUGH, Mass., March 2, 2022 /PRNewswire/ -- Boston Scientific Corporation (the "Company") (NYSE:BSX) today announced the commencement of a cash tender offer (the "Tender Offer") for up to $2.5 billion aggregate principal amount (the "Aggregate Maximum Principal Amount") of the outstanding senior notes listed in the table below (the "Securities").

Boston Scientific Announces Cash Tender Offer for up to $2.5 Billion of Its Outstanding Debt Securities

MARLBOROUGH, Mass., Feb. 28, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced positive results from a new analysis assessing real-world outcomes with the WATCHMAN FLX™ Left Atrial Appendage Closure (LAAC) Device.

Late-Breaking Study Results Reinforce Positive Real-World Outcomes with the WATCHMAN FLX™ LAAC Device

Fidelity National Information

Roivant Sciences Ltd

Twilio

Workday

Viking Global leader Andreas Halvorsen (Trades, Portfolio) disclosed his portfolio for the final quarter of 2021 last week.

Andreas Halvorsen Loads Up on Health Care, Tech Stocks

Intuitive Surgical

The decline from September 2021 in Medical Device stocks was healthy. Similar price structures provide confidence in coming upside.

Riding The Stock Waves: Update On The Medical Devices Sector

The U.S. Federal Trade Commission said it has approved certain modifications to medical device company Boston Scientific Corp's divestiture agreements.

FTC approves modifications to Boston Scientific divestiture agreement

We believe that Boston Scientific stock is a good buying opportunity at the current levels. Earlier this month the company released its Q4 earnings, which were better than our estimates.

Is Boston Scientific Stock A Good Buy At $43?

MARLBOROUGH, Mass., Feb. 15, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced the close of its acquisition of Baylis Medical Company Inc., a company that offers advanced transseptal access solutions as well as guidewires, sheaths and dilators used to support catheter-based left-heart procedures.

Boston Scientific Closes Acquisition of Baylis Medical Company Inc.

MARLBOROUGH, Mass., Feb. 14, 2022 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) will participate in SVB Leerink's 11th Annual Global Healthcare Conference on Thursday, February 17, 2022.

Boston Scientific to Participate in 11th Annual SVB Leerink Global Healthcare Conference

Boston Scientific (BSX) registers a year-over-year improvement in organic sales, indicating a strong rebound in legacy business from pandemic mayhem.

Boston Scientific (BSX) Q4 Earnings Top Estimates, Margins Up

Boston Scientific Corporation (BSX) CEO Mike Mahoney on Q4 2021 Results - Earnings Call Transcript

News for Boston Scientific Stock (BSX)